Cargando…

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting

Despite the recent success of CAR T cells targeting CD19 and CD22 in hematological malignancies, the production of CAR T cells still requires an extensive manufacturing process. The well-established NK-92 cell line provides a promising alternative to produce CAR-modified effector cells in a GMP-comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grote, Stefan, Mittelstaet, Joerg, Baden, Caroline, Chan, Kenneth Chun-Ho, Seitz, Christian, Schlegel, Patrick, Kaiser, Andrew, Handgretinger, Rupert, Schleicher, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781805/ https://www.ncbi.nlm.nih.gov/pubmed/33457105 http://dx.doi.org/10.1080/2162402X.2020.1825177

Ejemplares similares

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)

In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment
por: Grote, Stefan, et al.
Publicado: (2021)

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
por: Cutmore, Lauren C., et al.
Publicado: (2021)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting
por: Seitz, Christian M., et al.
Publicado: (2021)

Adherence to COPD treatment in Turkey and Saudi Arabia: results of the ADCARE study
por: Kokturk, Nurdan, et al.
Publicado: (2018)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
por: Lu, Shi‐Jiang, et al.
Publicado: (2021)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
por: Aparicio, Cristina, et al.
Publicado: (2023)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Transient Chimeric Ad5/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells
por: Gao, Jian, et al.
Publicado: (2020)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2021)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

A concept for integrated care pathways for atopic dermatitis—A GA(2)LEN ADCARE initiative
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia
por: Pfeiffer, Matthias Manuel, et al.
Publicado: (2013)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
por: Seitz, Christian M., et al.
Publicado: (2019)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
por: Zhang, Jianguang, et al.
Publicado: (2019)

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
por: Zhang, Qing, et al.
Publicado: (2018)

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
por: Zuo, Pengcheng, et al.
Publicado: (2023)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8lvkrn2nlk61jupvoonagkoqo1